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Neurodegenerative Dis 2012;10:257-260 258 sional or clinically associated with atypical parkinsonism. The LRRK2 and PRKN mutations are the most prevalent [4, 5] . The SNCA and LRRK2 mutations are pathologically characterized by ␣ -synuclein deposition, albeit in some LRRK2 cases, tau and TDP-43 pathologies were identified [6] . The knowledge about the pathology of PRKN, PINK1, and DJ1 is limited due to a small number of examined gene carriers, and therefore awaits further detailed assessments. Table 2 summarizes the current status of non-PARK loci/genes associated with the parkinsonian phenotype in some affected cases. However, it should be emphasized that in the majority of these cases, the clinical phenotype is usually dominated by other signs such as ataxia, chorea, dystonia, and/or dementia. The mode of inheritance varies and can be autosomal dominant, autosomal recessive, X-linked, or mitochondrial. Parkinsonism is most consistently seen in spinocerebellar ataxia type 3, spinocerebellar ataxia type 12, frontotemporal dementia with parkinsonism linked to chromosome 17 with tau pathology and in Perry syndrome [7] [8] [9] . The pathology varies depending on the specific gene.
Non-PARK Loci/Genes

Newly Identified PD Genes
Recently, several genes associated with PD (some are listed in table 3 ) have been identified; among them, GBA mutations are the most prevalent, particularly in the Ashkenazi Jewish population [10] . Very little is known about the prevalence of the eIF4G1 and VPS35 genes but inheritance is autosomal dominant [11, 12] . Both genes, eIF4G1 and VPS35, have been identified only in few families, but these families are from different European and North American countries [11] [12] [13] . The phenotype is consistent with levodopa-responsive PD, but in some cases dementia is present. The pathology of eIF4G1 is of the ␣ -synuclein type. To date, the pathology of VPS35 is relatively unknown. 
S NCA = ␣-Synuclein; PRKN = parkin; UCHL1 = ubiquitin carboxyl-terminal esterase L1; PINK1 = PTENinduced putative kinase 1; LRRK2 = leucine-rich repeat kinase 2; ATP13A2 = ATPase type 13A2; GIGYF2 = Grb10-interacting GYF protein 2; HtrA2 = HtrA serine peptidase 2; PLA2G6 = phospholipase A2, group 6; FBXO7 = F-box protein 7; GAK = cyclin G-associated kinase; HLA-DRA = major histocompatibility complex, class II, DR ␣; AD = autosomal dominant; AR = autosomal recessive.
a Provisional loci/genes awaiting further confirmation. b Provisional loci/genes identified through the recent genome-wide association studies also awaiting further confirmation. The field of the genetics of PD/parkinsonism is evolving at a high speed. There will be many more genes identified as studies progress. For example, the Mayo Clinic Florida collection of PD/parkinsonism families contains more than 800 kindred, but the genetic defect for the majority of them is unknown. The current classification of PD loci and genes based on PARK and non-PARK categories is misleading and imprecise. It does not reflect the clinical presentation of certain gene carriers (for example, carriers of the PARK9/ ATP13A2 gene present at a very early age and with a mixed phenotype consistent with atypical parkinsonism). The current pathological classifications based on protein product/inclusion accumulation in the brain are also imprecise since there are cases from the same family, carriers of the same genetic mutation (for example , LRRK2, R1441C or I2020T), that have pleomorphic pathology. Therefore, better classifications of the neurodegenerative conditions associated with a parkinsonian phenotype need to be devised. We hope that therapeutic interventions will be forthcoming based on the identification of these genes.
